Logo

Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies

Share this

Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies

Shots:

  • oNKo-innate to receive an up front- clinical- regulatory & commercial milestones along with royalties on sales of immuno-oncology and cell therapy programs while in exchange- the company will utilize its genome-wide screening techniques and technology platform to discover novel immune cell targets enhancing NK cell anti-tumor immunity and to create NK cell therapies
  • oNKo-innate will execute screens to identify and validate targets to seed internal Gilead’s immuno-oncology discovery programs. For Kite’s development of next-generation cell therapies- oNKo-innate will create and evaluate NK constructs
  • The alliance will expand Kite’s capabilities to identify NK cell therapies and advance it toward clinical development while supports Gilead’s efforts to develop novel cancer therapies

Click here ­to­ read full press release/ article 

Ref: Gilead  | Image: Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions